BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 6439588)

  • 1. myo-Inositol and sorbitol in erythrocytes from diabetic patients before and after sorbinil treatment.
    Popp-Snijders C; Lomecky-Janousek MZ; Schouten JA; van der Veen EA
    Diabetologia; 1984 Nov; 27(5):514-6. PubMed ID: 6439588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
    Gillon KR; Hawthorne JN; Tomlinson DR
    Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
    Schmidt RE; Plurad SB; Sherman WR; Williamson JR; Tilton RG
    Diabetes; 1989 May; 38(5):569-79. PubMed ID: 2497038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with aldose reductase inhibitor or with myo-inositol arrests deterioration of the electroretinogram of diabetic rats.
    MacGregor LC; Matschinsky FM
    J Clin Invest; 1985 Aug; 76(2):887-9. PubMed ID: 3928685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of aldose reductase inhibition on erythrocyte polyols and galactitol accumulation in diabetic patients.
    Airey CM; Price DE; Kemp JV; Perkins CM; Wales JK
    Diabet Med; 1989 Dec; 6(9):804-8. PubMed ID: 2533041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sorbinil treatment on erythrocytes and platelets of persons with diabetes.
    Martyn CN; Matthews DM; Popp-Snijders C; Tucker J; Ewing DJ; Clarke BF
    Diabetes Care; 1986; 9(1):36-9. PubMed ID: 3948646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased nerve polyol levels in experimental diabetes and their reversal by Sorbinil.
    Whiting PH; Ross IS
    Br J Exp Pathol; 1988 Oct; 69(5):697-702. PubMed ID: 3143396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil.
    Beyer-Mears A; Ku L; Cohen MP
    Diabetes; 1984 Jun; 33(6):604-7. PubMed ID: 6427041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
    Yue DK; Hanwell MA; Satchell PM; Handelsman DJ; Turtle JR
    Metabolism; 1984 Dec; 33(12):1119-22. PubMed ID: 6438438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Na+-K+-ATPase pumping activity is not directly linked to myo-inositol levels after sorbinil treatment in lenses of diabetic rats.
    Yeh LA; Rafford CE; Goddu KJ; Ashton MA; Beyer TA; Hutson NJ
    Diabetes; 1987 Dec; 36(12):1414-9. PubMed ID: 2824260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The penetration of Sorbinil, an aldose reductase inhibitor, into lens, aqueous humour and erythrocytes of patients undergoing cataract extraction.
    Crabbe MJ; Petchey M; Burgess SE; Cheng H
    Exp Eye Res; 1985 Jan; 40(1):95-9. PubMed ID: 3920064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor.
    Greene DA; Lattimer SA
    Am J Med; 1985 Nov; 79(5A):13-7. PubMed ID: 3000175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy.
    Dyck PJ; Zimmerman BR; Vilen TH; Minnerath SR; Karnes JL; Yao JK; Poduslo JF
    N Engl J Med; 1988 Sep; 319(9):542-8. PubMed ID: 3136330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function.
    Martyn CN; Reid W; Young RJ; Ewing DJ; Clarke BF
    Diabetes; 1987 Sep; 36(9):987-90. PubMed ID: 3111914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A; Cruz E
    Diabetes; 1985 Jan; 34(1):15-21. PubMed ID: 3917257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An aldose reductase inhibitor but not myo-inositol blocks enhanced polyphosphoinositide turnover in peripheral nerve from diabetic rats.
    Berti-Mattera L; Day N; Peterson RG; Eichberg J
    Metabolism; 1996 Mar; 45(3):320-7. PubMed ID: 8606638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
    Tomlinson DR; Moriarty RJ; Mayer JH
    Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)].
    Christensen JE; Larsen AB; Gregersen G
    Ugeskr Laeger; 1987 Nov; 149(46):3111-4. PubMed ID: 3127975
    [No Abstract]   [Full Text] [Related]  

  • 19. Aldose reductase, glomerular metabolism, and diabetic nephropathy.
    Cohen MP
    Metabolism; 1986 Apr; 35(4 Suppl 1):55-9. PubMed ID: 3007926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study.
    Christensen JE; Varnek L; Gregersen G
    Acta Neurol Scand; 1985 Feb; 71(2):164-7. PubMed ID: 3920861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.